Reduced-intensity conditioning followed by T-cell depleted allogeneic stem cell transplantation for patients with chronic myeloid leukaemia and minimal residual disease at the time of transplant: high risk of molecular relapse

Br J Haematol. 2007 Jan;136(1):127-30. doi: 10.1111/j.1365-2141.2006.06404.x.

Abstract

A pilot trial was initiated for chronic myeloid leukaemia patients, which employed imatinib for remission induction, followed by reduced-intensity conditioning and an in vivo T-cell depleted graft. Out of nine patients, six experienced a molecular relapse and one patient had a haematological relapse at a median interval of 5 months after transplantation. Five relapsing patients achieved a 2nd molecular remission after treatment with either donor lymphocyte infusions (n = 4) or imatinib (n = 1). Two of nine patients died due to infectious complications. The probability of survival 2 years after transplant was 74% (95% CI 42-100%).

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Benzamides
  • Female
  • Fusion Proteins, bcr-abl
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Imatinib Mesylate
  • Immunosuppressive Agents / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / surgery*
  • Lymphocyte Depletion / methods*
  • Male
  • Middle Aged
  • Neoplasm, Residual / immunology
  • Neoplasm, Residual / mortality
  • Neoplasm, Residual / surgery*
  • Pilot Projects
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Recurrence
  • Risk
  • Survival Rate
  • Transplantation Conditioning / methods*
  • Transplantation, Homologous

Substances

  • Benzamides
  • Immunosuppressive Agents
  • Piperazines
  • Pyrimidines
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl